2026 Q3 - tulosraportti
7 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 140 | ||
| 6 000 | ||
| 4 000 | ||
| 2 000 | ||
| 1 129 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 22.10.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·5 t sitten · MuokattuLager status Privatrezept has sold out at 1 pharmacy Flowzs has sold out at 1 pharmacy Medcanonestop has sold out at 1 pharmacy Something has started to happen again with the sales of Weeco Astrum10/10. It supports what was said at the last webcast, that sales are starting to pick up again.Cannanow has three pharmacies that have Weeco Astrum10/10 in stock. They have had it for a while, but a combination of my poor German skills and them having changed their layout, I have overlooked it.- ·1 päivä sitteninventory status the warehouse in Dusseldorf has been sold out, but has got the oil in stock again, and they have raised the price. It is good information that they have raised the price, because they will only do that when there is a good flow over the counter. If there were not customers buying the oil they would lower the price. ( This naturally does not apply to customers who are insured)
- ·31.10.This study shows that German medical cannabis users prefer to get a prescription for the medicine rather than buying it on the street without a prescription. First of all because it is more stressful to buy it on the street, but it is also uncertain how pure the product is compared to the pharmacy, and then it is cheaper at the pharmacy than on the street. If you are covered by insurance, it is free. This is good news for Astrum10/10, because you can only get the oil with a prescription. (flower medicine is status quo with reimbursement) https://www.mmjdaily.com/article/9886213/bloomwell-survey-finds-pharmacy-cannabis-causes-four-times-less-stress-than-illegal-market/
This study shows that German users of medical cannabis prefer to get a prescription for the medicine rather than buying it on the street without a prescription. First of all because it is more stressful to buy it on the street, but it is also uncertain how pure the product is compared to the pharmacy and then it is cheaper at the pharmacy than on the street. If you are covered by insurance, then it is free. Holy shit. That probably doesn't apply only to the Germans, but everyone in the whole world.. Legal, safe, better and cheaper/free.... Hmmmm yeah that's a tough one, there is also that shady guy down on the corner..... SUK!!!!!!!!!! 
·29.10.They came with a teaser that they are looking forward to telling us about what solution there is regarding the flower medicine in Denmark. And that they also emphasized that the relaxed rules in Germany, that Weeco Astrum 10/10 is no longer affected by the quarantine (apart from 4-5 diseases that are forced to use medicine approved for these), has made the sales of Weeco Astrum 10/10 in Germany get back on the sales track again. I think that Q4 will also blow the roof off Stenocare's revenues, as it has done now for 6 quarters in a row. https://cannabis-startups.com/bundestag-backtracks-6-month-rule-for-medical-cannabis-scrapped-flower-stays-excluded/- ·29.10.STENOCARE reports 53% revenue growth in Q3 2026 and maintains ambition for positive full-year EBITDA STENOCARE delivered significant revenue growth in the third quarter of 2026, driven by strong performance in the Danish core market. Regulatory changes in Germany and a temporary drop in earnings, however, ended a streak of positive quarterly EBITDA results, although the company continues to aim for a profitable full year. Looking ahead, the company is actively working to secure its supply chain for dried flowers and prepare for new opportunities in France. Net revenue in Q3 increased by 53 % year-on-year to 2.935 million DKK, while revenue for the first nine months increased by 125 % to 9.935 million DKK. EBITDA for the quarter was negative by 244 thousand DKK, ending five consecutive quarters of positive EBITDA, although EBITDA for the full year is still expected to be positive. Cash flow from operations for the first nine months of 2026 was positive by 0.8 million DKK, and cash and cash equivalents amounted to 0.6 million DKK as of 30 September 2026. The company is actively seeking alternative suppliers to mitigate potential supply shortages for Bedrocan products from 2027 onwards as a result of changes in Dutch export policy. Sales in Germany were below expectations due to changes in prescription and reimbursement requirements, but the company continues its commercial and educational efforts there. https://www.nordnet.dk/markedet/nyheder/ad687fac-db3c-4dbc-9008-1ca5d7f59cfd
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
7 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sitten · MuokattuLager status Privatrezept has sold out at 1 pharmacy Flowzs has sold out at 1 pharmacy Medcanonestop has sold out at 1 pharmacy Something has started to happen again with the sales of Weeco Astrum10/10. It supports what was said at the last webcast, that sales are starting to pick up again.Cannanow has three pharmacies that have Weeco Astrum10/10 in stock. They have had it for a while, but a combination of my poor German skills and them having changed their layout, I have overlooked it.
- ·1 päivä sitteninventory status the warehouse in Dusseldorf has been sold out, but has got the oil in stock again, and they have raised the price. It is good information that they have raised the price, because they will only do that when there is a good flow over the counter. If there were not customers buying the oil they would lower the price. ( This naturally does not apply to customers who are insured)
- ·31.10.This study shows that German medical cannabis users prefer to get a prescription for the medicine rather than buying it on the street without a prescription. First of all because it is more stressful to buy it on the street, but it is also uncertain how pure the product is compared to the pharmacy, and then it is cheaper at the pharmacy than on the street. If you are covered by insurance, it is free. This is good news for Astrum10/10, because you can only get the oil with a prescription. (flower medicine is status quo with reimbursement) https://www.mmjdaily.com/article/9886213/bloomwell-survey-finds-pharmacy-cannabis-causes-four-times-less-stress-than-illegal-market/This study shows that German users of medical cannabis prefer to get a prescription for the medicine rather than buying it on the street without a prescription. First of all because it is more stressful to buy it on the street, but it is also uncertain how pure the product is compared to the pharmacy and then it is cheaper at the pharmacy than on the street. If you are covered by insurance, then it is free. Holy shit. That probably doesn't apply only to the Germans, but everyone in the whole world.. Legal, safe, better and cheaper/free.... Hmmmm yeah that's a tough one, there is also that shady guy down on the corner..... SUK!!!!!!!!!!
- ·29.10.They came with a teaser that they are looking forward to telling us about what solution there is regarding the flower medicine in Denmark. And that they also emphasized that the relaxed rules in Germany, that Weeco Astrum 10/10 is no longer affected by the quarantine (apart from 4-5 diseases that are forced to use medicine approved for these), has made the sales of Weeco Astrum 10/10 in Germany get back on the sales track again. I think that Q4 will also blow the roof off Stenocare's revenues, as it has done now for 6 quarters in a row. https://cannabis-startups.com/bundestag-backtracks-6-month-rule-for-medical-cannabis-scrapped-flower-stays-excluded/
- ·29.10.STENOCARE reports 53% revenue growth in Q3 2026 and maintains ambition for positive full-year EBITDA STENOCARE delivered significant revenue growth in the third quarter of 2026, driven by strong performance in the Danish core market. Regulatory changes in Germany and a temporary drop in earnings, however, ended a streak of positive quarterly EBITDA results, although the company continues to aim for a profitable full year. Looking ahead, the company is actively working to secure its supply chain for dried flowers and prepare for new opportunities in France. Net revenue in Q3 increased by 53 % year-on-year to 2.935 million DKK, while revenue for the first nine months increased by 125 % to 9.935 million DKK. EBITDA for the quarter was negative by 244 thousand DKK, ending five consecutive quarters of positive EBITDA, although EBITDA for the full year is still expected to be positive. Cash flow from operations for the first nine months of 2026 was positive by 0.8 million DKK, and cash and cash equivalents amounted to 0.6 million DKK as of 30 September 2026. The company is actively seeking alternative suppliers to mitigate potential supply shortages for Bedrocan products from 2027 onwards as a result of changes in Dutch export policy. Sales in Germany were below expectations due to changes in prescription and reimbursement requirements, but the company continues its commercial and educational efforts there. https://www.nordnet.dk/markedet/nyheder/ad687fac-db3c-4dbc-9008-1ca5d7f59cfd
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 140 | ||
| 6 000 | ||
| 4 000 | ||
| 2 000 | ||
| 1 129 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 22.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
7 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 22.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sitten · MuokattuLager status Privatrezept has sold out at 1 pharmacy Flowzs has sold out at 1 pharmacy Medcanonestop has sold out at 1 pharmacy Something has started to happen again with the sales of Weeco Astrum10/10. It supports what was said at the last webcast, that sales are starting to pick up again.Cannanow has three pharmacies that have Weeco Astrum10/10 in stock. They have had it for a while, but a combination of my poor German skills and them having changed their layout, I have overlooked it.
- ·1 päivä sitteninventory status the warehouse in Dusseldorf has been sold out, but has got the oil in stock again, and they have raised the price. It is good information that they have raised the price, because they will only do that when there is a good flow over the counter. If there were not customers buying the oil they would lower the price. ( This naturally does not apply to customers who are insured)
- ·31.10.This study shows that German medical cannabis users prefer to get a prescription for the medicine rather than buying it on the street without a prescription. First of all because it is more stressful to buy it on the street, but it is also uncertain how pure the product is compared to the pharmacy, and then it is cheaper at the pharmacy than on the street. If you are covered by insurance, it is free. This is good news for Astrum10/10, because you can only get the oil with a prescription. (flower medicine is status quo with reimbursement) https://www.mmjdaily.com/article/9886213/bloomwell-survey-finds-pharmacy-cannabis-causes-four-times-less-stress-than-illegal-market/This study shows that German users of medical cannabis prefer to get a prescription for the medicine rather than buying it on the street without a prescription. First of all because it is more stressful to buy it on the street, but it is also uncertain how pure the product is compared to the pharmacy and then it is cheaper at the pharmacy than on the street. If you are covered by insurance, then it is free. Holy shit. That probably doesn't apply only to the Germans, but everyone in the whole world.. Legal, safe, better and cheaper/free.... Hmmmm yeah that's a tough one, there is also that shady guy down on the corner..... SUK!!!!!!!!!!
- ·29.10.They came with a teaser that they are looking forward to telling us about what solution there is regarding the flower medicine in Denmark. And that they also emphasized that the relaxed rules in Germany, that Weeco Astrum 10/10 is no longer affected by the quarantine (apart from 4-5 diseases that are forced to use medicine approved for these), has made the sales of Weeco Astrum 10/10 in Germany get back on the sales track again. I think that Q4 will also blow the roof off Stenocare's revenues, as it has done now for 6 quarters in a row. https://cannabis-startups.com/bundestag-backtracks-6-month-rule-for-medical-cannabis-scrapped-flower-stays-excluded/
- ·29.10.STENOCARE reports 53% revenue growth in Q3 2026 and maintains ambition for positive full-year EBITDA STENOCARE delivered significant revenue growth in the third quarter of 2026, driven by strong performance in the Danish core market. Regulatory changes in Germany and a temporary drop in earnings, however, ended a streak of positive quarterly EBITDA results, although the company continues to aim for a profitable full year. Looking ahead, the company is actively working to secure its supply chain for dried flowers and prepare for new opportunities in France. Net revenue in Q3 increased by 53 % year-on-year to 2.935 million DKK, while revenue for the first nine months increased by 125 % to 9.935 million DKK. EBITDA for the quarter was negative by 244 thousand DKK, ending five consecutive quarters of positive EBITDA, although EBITDA for the full year is still expected to be positive. Cash flow from operations for the first nine months of 2026 was positive by 0.8 million DKK, and cash and cash equivalents amounted to 0.6 million DKK as of 30 September 2026. The company is actively seeking alternative suppliers to mitigate potential supply shortages for Bedrocan products from 2027 onwards as a result of changes in Dutch export policy. Sales in Germany were below expectations due to changes in prescription and reimbursement requirements, but the company continues its commercial and educational efforts there. https://www.nordnet.dk/markedet/nyheder/ad687fac-db3c-4dbc-9008-1ca5d7f59cfd
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 140 | ||
| 6 000 | ||
| 4 000 | ||
| 2 000 | ||
| 1 129 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt